# EDGAR Filing Document

**Accession Number:** 0001202102
**File Stem:** 0001209191-23-011387
**Filing Date:** 2023-2
**Character Count:** 8669
**Document Hash:** 8fb55694b60e877ed8ca304d59e1f2ee
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001209191-23-011387.hdr.sgml**: 20230221

**ACCESSION NUMBER**: 0001209191-23-011387

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230217

**FILED AS OF DATE**: 20230221

**DATE AS OF CHANGE**: 20230221

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** SCANGOS GEORGE A
- **CENTRAL INDEX KEY:** 0001202102

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39083
- **FILM NUMBER:** 23650094

**MAIL ADDRESS:**
- **STREET 1:** C/O EXELIXIS INC
- **STREET 2:** 170 HARBOR WAY
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94083
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Vir Biotechnology, Inc.
- **CENTRAL INDEX KEY:** 0001706431
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 812730369
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 499 ILLINOIS STREET
- **STREET 2:** SUITE 500
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94158
- **BUSINESS PHONE:** 415-906-4324

**MAIL ADDRESS:**
- **STREET 1:** 499 ILLINOIS STREET
- **STREET 2:** SUITE 500
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94158

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>SCANGOS GEORGE A<br><sub>(Last) (First) (Middle)</sub><br>C/O VIR BIOTECHNOLOGY, INC.<br>499 ILLINOIS STREET, SUITE 500<br><sub>(Street)</sub><br>SAN FRANCISCO, CA 94158<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-02-17 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_President and CEO_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Vir Biotechnology, Inc. [ VIR ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2022-12-21 |  | J<sup>(1)</sup> |  | 49984 | D | $0.00 | 827151 | I | See footnote<sup>(2)</sup> |
| Common Stock | 2022-12-21 |  | J<sup>(1)</sup> |  | 49984 | A | $0.00 | 111644 | I | See footnote<sup>(3)</sup> |
| Common Stock | 2022-12-21 |  | J<sup>(1)</sup> |  | 49984 | D | $0.00 | 827151 | I | See footnote<sup>(4)</sup> |
| Common Stock | 2022-12-21 |  | J<sup>(1)</sup> |  | 49984 | A | $0.00 | 111644 | I | See footnote<sup>(5)</sup> |
| Common Stock | 2023-01-18 |  | J<sup>(1)</sup> |  | 64930 | D | $0.00 | 3533629 | I | See footnote<sup>(6)</sup> |
| Common Stock | 2023-01-18 |  | J<sup>(1)</sup> |  | 64930 | A | $0.00 | 179930 | I | See footnote<sup>(7)</sup> |
| Common Stock | 2023-02-17 |  | S<sup>(8)</sup> |  | 9894 | D | $25.288 | 214095 | D |  |
| Common Stock | 2023-02-21 |  | S<sup>(9)</sup> |  | 11382 | D | 28.015<sup>(10)</sup> | 202713 | D |  |
| Common Stock | 2023-02-21 |  | S<sup>(9)</sup> |  | 6474 | D | 28.80<sup>(11)</sup> | 196239 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

---

### Footnotes:

(1) Transfer without consideration for tax planning purposes.

(2) The shares are held in the name of the Jennifer Scangos 2018 Non-Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees.

(3) The shares are held in the name of the Jennifer Scangos 2018 Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees.

(4) The shares are held in the name of the Katherine Scangos 2018 Non-Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees.

(5) The shares are held in the name of the Katherine Scangos 2018 Exempt Trust, dated August 30, 2018, of which the reporting person and his spouse are Trustees.

(6) The shares are held in the name of George A. Scangos, as Trustee of the Scangos-Wilson Family Trust dated May 12, 2011.

(7) The shares are held in the name of the Scangos 2018 Grandchildren's Trust, of which the reporting person and his spouse are Trustees.

(8) Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.

(9) Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 29, 2022.

(10) The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.49 to $28.44 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

(11) The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.51 to $29.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

**Signature:** /s/ Howard Horn, Attorney-in-Fact  
**Date:** 2023-02-21

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**